Literature DB >> 7748045

Long-term outcomes of deep-vein thrombosis.

R J Beyth1, A M Cohen, C S Landefeld.   

Abstract

OBJECTIVE: To assess the long-term outcomes of patients with acute deep-vein thrombosis.
METHODS: We followed up 124 patients with deep-vein thrombosis 6 to 8 years after the index thrombosis to determine the frequency of death, recurrent venous thromboembolism, postphlebitic symptoms, and their relationship to three domains of health-related quality of life.
RESULTS: Fifty-two (42%) of the 124 patients died. The cumulative incidence of death was 17% at 1 year and 39% at 5 years. Death was especially common among patients older than 75 years and those with cancer or stroke (5-year cumulative incidence, 66%, compared with 12% among other patients; P < .0001). Most deaths were attributable to cancer or cardiovascular disease. Venous thromboembolism recurred in 18 patients (15%); the cumulative incidence was 6% at 1 year and 13% at 5 years. Recurrence was more common, however, among patients younger than 65 years with a history of recurrent venous thromboembolism (5-year cumulative incidence, 34%, compared with 10% among other patients; P < .01). In interviews with 52 patients 6 to 8 years after the index deep-vein thrombosis, 42% reported pain, swelling, or discoloration in the leg affected by the index thrombosis. Perceptions of health, physical functioning, and role limitations attributed to physical health were worse (P < .01 for each domain) in symptomatic patients than in asymptomatic patients.
CONCLUSIONS: Six to 8 years after deep-vein thrombosis, many patients had died of preexisting cancer or cardiovascular disease. Recurrent venous thromboembolism was uncommon. Symptoms in the leg affected by the index thrombosis were common, however, and were associated with worse health-related quality of life.

Entities:  

Mesh:

Year:  1995        PMID: 7748045

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  29 in total

1.  Value-of-information analysis to reduce decision uncertainty associated with the choice of thromboprophylaxis after total hip replacement in the Irish healthcare setting.

Authors:  Laura McCullagh; Cathal Walsh; Michael Barry
Journal:  Pharmacoeconomics       Date:  2012-10-01       Impact factor: 4.981

2.  Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Clive Kearon; Elie A Akl; Anthony J Comerota; Paolo Prandoni; Henri Bounameaux; Samuel Z Goldhaber; Michael E Nelson; Philip S Wells; Michael K Gould; Francesco Dentali; Mark Crowther; Susan R Kahn
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

3.  Methodology for the development of antithrombotic therapy and prevention of thrombosis guidelines: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Gordon H Guyatt; Susan L Norris; Sam Schulman; Jack Hirsh; Mark H Eckman; Elie A Akl; Mark Crowther; Per Olav Vandvik; John W Eikelboom; Marian S McDonagh; Sandra Zelman Lewis; David D Gutterman; Deborah J Cook; Holger J Schünemann
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

Review 4.  The post-thrombotic syndrome: the forgotten morbidity of deep venous thrombosis.

Authors:  Susan R Kahn
Journal:  J Thromb Thrombolysis       Date:  2006-02       Impact factor: 2.300

5.  Thrombolytic therapy for deep vein thrombosis.

Authors:  Suresh Vedantham
Journal:  Curr Treat Options Cardiovasc Med       Date:  2009-04

6.  The VEINES-QOL/Sym questionnaire is a reliable and valid disease-specific quality of life measure for deep vein thrombosis in elderly patients.

Authors:  M Méan; A Limacher; S R Kahn; D Aujesky
Journal:  Qual Life Res       Date:  2014-05-04       Impact factor: 4.147

7.  Venous thromboembolism and subsequent permanent work-related disability.

Authors:  S K Braekkan; S D Grosse; E M Okoroh; J Tsai; S C Cannegieter; I A Naess; S Krokstad; J-B Hansen; F E Skjeldestad
Journal:  J Thromb Haemost       Date:  2016-08-17       Impact factor: 5.824

Review 8.  Cost effectiveness of desirudin compared with a low molecular weight heparin in the prevention of deep vein thrombosis after total hip replacement surgery.

Authors:  L A Levin; D Bergqvist
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

Review 9.  Endovascular Interventions for Acute and Chronic Lower Extremity Deep Venous Disease: State of the Art.

Authors:  Akhilesh K Sista; Suresh Vedantham; John A Kaufman; David C Madoff
Journal:  Radiology       Date:  2015-07       Impact factor: 11.105

10.  Venous claudication in iliofemoral thrombosis: long-term effects on venous hemodynamics, clinical status, and quality of life.

Authors:  Konstantinos T Delis; Dimitris Bountouroglou; Averil O Mansfield
Journal:  Ann Surg       Date:  2004-01       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.